A recently identified blood biomarker, activin A, may prove useful in the early detection of mesothelioma. Equally promising, this new biomarker may even allow for greater personalization of mesothelioma treatments by accurately identifying which patients would benefit from a multimodal treatment approach and which would find greater benefit from a singular treatment option. However, while the diagnostic and prognostic benefits of this newly identified biomarker will likely be of immediate use, development of its therapeutic uses may be years away.
Activin A is a protein complex found in the blood. In this most recent study, blood levels of activin A were measured in 129 patients across four international locations. 45 healthy patients were included for comparison. This biomarker was found in significantly higher levels in patients with mesothelioma and seemed to correspond to increased tumor volume. Because even a slight increase in activin A can indicate the presence of mesothelioma, earlier diagnosis through a noninvasive blood biomarker test is possible. Early diagnosis allows for prompt treatment that can slow the progression of malignant mesothelioma and help improve both quality of life and lifespan in patients with this rare and deadly disease.
Diagnosing and treating mesothelioma can be cost prohibitive, but people who have been exposed to asbestos – occupationally or otherwise – are often entitled to compensation for these and related expenses. NYC mesothelioma lawyer Joseph Williams welcomes an opportunity to meet with you free of charge and obligation to discuss you case, your rights, and the most effective way to get the treatment you deserve.
To schedule your initial consultation at our New York City office, please contact The Williams Law Firm online or by calling 855-575-MESO (6376) today. Attorney Williams serves victims of asbestos-related illness living in all areas of the country.